Fabien Praz
A5048697529- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Cardiovascular Function and Risk Factors
- Cardiac Structural Anomalies and Repair
- Cardiac Imaging and Diagnostics
- Atrial Fibrillation Management and Outcomes
- Coronary Interventions and Diagnostics
- Aortic Disease and Treatment Approaches
- Cardiac pacing and defibrillation studies
- Cardiac Arrhythmias and Treatments
- Acute Myocardial Infarction Research
- Pulmonary Hypertension Research and Treatments
- Cardiovascular and Diving-Related Complications
- Traumatic Brain Injury and Neurovascular Disturbances
- Antiplatelet Therapy and Cardiovascular Diseases
- Congenital Heart Disease Studies
- Cardiovascular Issues in Pregnancy
- Venous Thromboembolism Diagnosis and Management
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac electrophysiology and arrhythmias
- COVID-19 and healthcare impacts
- Cardiac and Coronary Surgery Techniques
- Intracranial Aneurysms: Treatment and Complications
- Mechanical Circulatory Support Devices
- Vascular anomalies and interventions
University of Bern
2016-2025
University Hospital of Bern
2016-2025
Medical University of Vienna
2017-2024
Swiss Continence Foundation
2021
New York Hospital Queens
2017-2020
NewYork–Presbyterian Hospital
2017-2020
University of Zurich
2020
Ludwig-Maximilians-Universität München
2020
Columbia University Irving Medical Center
2017-2019
Texas Health Dallas
2019
Guidelines •
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their dating.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use care therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical judgment as...
Approximately 4% of subjects aged 75 years or more have clinically relevant tricuspid regurgitation (TR). Primary TR results from anatomical abnormality the valve apparatus and is observed in only 8-10% patients with disease. Secondary common arises as a result annular dilation caused by right ventricular enlargement dysfunction consequence pulmonary hypertension, often left-sided heart disease atrial fibrillation. Irrespective its aetiology, leads to volume overload increased wall stress,...
Aims: The Academic Research Consortium for High Bleeding Risk (ARC-HBR) defined consensus-based criteria patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI). We aimed to validate the ARC-HBR outcomes using a large cohort of PCI. Methods and results: Between 2009 2016, PCI were prospectively included in Bern Registry. Patients considered be HBR if least one major criterion or two minor met. primary endpoint was (BARC) 3 5 year; ischaemic assessed...
Secondary (or functional) mitral regurgitation (SMR) occurs frequently in chronic heart failure (HF) with reduced left ventricular (LV) ejection fraction, resulting from LV remodelling that prevents coaptation of the valve leaflets. contributes to progression symptoms and signs HF confers worse prognosis. The management patients SMR is complex requires timely referral a multidisciplinary Heart Team. Optimization pharmacological device therapy according guideline recommendations crucial....
Severe tricuspid regurgitation (TR) is known to be associated with substantial morbidity and mortality.The authors sought study the acute outcomes of subjects treated by transcatheter edge-to-edge repair TriClip system (Abbott) in a contemporary, real-world setting.The bRIGHT (An Observational Real-World Study Evaluating Tricuspid Regurgitation Patients Treated With Abbott TriClip™ Device) postapproval prospective, single-arm, open-label, multicenter, postmarket registry conducted at 26...
Abstract Background and aims Benefit of tricuspid regurgitation (TR) correction timing intervention are unclear. This study aimed to compare survival rates after surgical or transcatheter conservative management according a TR clinical stage as assessed using the TRI-SCORE. Methods A total 2,413 patients with severe isolated functional were enrolled in TRIGISTRY (1217 conservatively managed, 551 valve surgery, 645 repair). The primary endpoint was at 2 years. Results TRI-SCORE low (≤3) 32%,...
Mitral regurgitation (MR) is the most prevalent valvular heart disease and, when left untreated, results in reduced quality of life, failure, and increased mortality. valve transcatheter edge-to-edge repair (M-TEER) has matured considerably as a non-surgical treatment option since its commercial introduction Europe 2008. As result major device interventional improvements, well accumulation experience by cardiologists, M-TEER emerged an important therapeutic strategy for patients with severe...
The role of cardiac implantable electronic device (CIED)-related tricuspid regurgitation (TR) is increasingly recognized as an independent clinical entity. Hence, interventional TR treatment options continuously evolve, surgical risk assessment and peri-operative care improve the management CIED-related TR, lead extraction high interest. Furthermore, novel valve are applied to patients suffering from associated with or related CIEDs. This multidisciplinary review article developed...
Abstract Atrial secondary tricuspid regurgitation (A-STR) is a distinct phenotype of with predominant dilation the right atrium and normal left ventricular function. occurs most commonly in elderly women atrial fibrillation heart failure preserved ejection fraction sinus rhythm. In A-STR, main mechanism leaflet malcoaptation related to presence significant annulus enlargement. addition, there an insufficient adaptive growth valve leaflets that become unable cover enlarged annular area. As...
Abstract Transcatheter tricuspid valve interventions (TTVI) are emerging as alternatives to surgery in high-risk patients with isolated or concomitant regurgitation. The development of new minimally invasive solutions potentially more adapted this largely undertreated population patients, has fuelled the interest for valve. Growing evidence and concepts have contributed revise obsolete misleading perceptions around right side heart. New definitions, classifications, a better understanding...
Abstract Background and Aims Risk stratification for mitral valve transcatheter edge-to-edge repair (M-TEER) is paramount in the decision-making process to appropriately select patients with severe secondary regurgitation (SMR). This study sought develop validate an artificial intelligence-derived risk score (EuroSMR score) predict 1-year outcomes (survival or survival + clinical improvement) SMR undergoing M-TEER. Methods An was developed from EuroSMR cohort (4172 428 treated M-TEER...